Abstract:Background Candida species are commonly detected as colonizers of the oral cavity; candidiasis or candidemia can develop in patients who are immunocompromised. Use of topical or inhaled glucocorticoids can alter the spectrum of Candida species and can promote oral candidiasis. The present study aims to evaluate the diversity of Candida species in the oral cavity and their susceptibility to antifungal agents in patients undergoing treatment with systemic glucocorticoids (SGCs) compared with non-users. Methods We conducted a descriptive, analytical, cross-sectional study that enrolled 120 patients with oral problems who were undergoing treatment with SGCs and who were admitted to the hospital of the First Affiliated Hospital, College of Medicine, Zhejiang University and Zhejiang Hospital, Hangzhou, China, between February 2019 and September 2019. One hundred and twenty age-and sex-matched patients were recruited as the SGC non-user control group. Demographic data included oral complaints and underlying diseases; symptoms of oral candidiasis were identified on physical examination. Candida species were collected using a concentrated oral rinse. Identification of fungal isolates was based on conventional phenotypic methods assisted by DNA sequence analysis of the internal transcribed spacer (ITS) rDNA gene region. Antifungal activities of anidulafungin, amphotericin B, micafungin, caspofungin, 5-flucytosine, posaconazole, voriconazole, itraconazole, and fluconazole were evaluated using the Sensititre YeastOneTM YO10 panel supplemented by the CLSI-M27-A3 protocol. Results Fifty-two (43.33%) out of the 120 patients undergoing with SGCs were diagnosed with oral candidiasis, compared with 14 (11.67%) of the non-users (P < 0.05). Likewise, we collected 88 strains from 73.33% of the SGC users compared with only 48 (40%) from non-users (P < 0.05). Candida albicans was detected most frequently in both groups (45.45% vs 66.67%, respectively; P = 0.033); the overall frequency of non-Candida albicans (NCA) strains isolated from patients treated with SGCs were significantly higher than that identified among non-users (51.14% vs 33.33%, respectively; P = 0.046), although there were no significant differences concerning any single species of NCA. Resistance of C. albicans to itraconazole (P = 0.004) and fluconazole (P = 0.001) was significantly higher in patients treated with SGCs than in non-users; however, echinocandins, amphotericin B, voriconazole, and posaconazole were all active against strains from both participant groups with no significant differences detected. Conclusion Taken together, our findings indicate that SGC therapy may result in an increased prevalence of oral candidiasis as reflected by the clinical presentations and strains isolated; these findings were also associated with an increased frequency of NCA strains. SGC therapy was also associated with an increased frequency of C. albicans strains that were resistant to both itraconazole and fluconazole. The impact of SGC therapy on Candida species in the oral cavity requires further study.

Oral candidiasis fl ora distribution and antifungal susceptibility test in vitro studies

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Antifungal Susceptibility Testing of Commensal and Pathogenic Clinical Isolates of Oral Candida

Oral Prevalence of Candida Species in Patients Undergoing Systemic Glucocorticoid Therapy and the Antifungal Sensitivity of the Isolates

Species distribution and antifungal susceptibility of Candida sp. isolates from AIDS patients with oropharyngeal candidiasis

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

SPECIES DISTRIBUTION OF CANDIDEMIA AND SUSCEPTIBILITY TO FLUCONAZOLE

In Vitro Antidrug Susceptibility Testing of Candida Species Isolated from Aseptic Body Fluids

Fluconazole susceptibility of 3,056 clinical isolates of Candida species from 2005 to 2009 in a tertiary-care hospital

Fluconazole Susceptibility and Genotypic Heterogeneity of Oral Candida Albicans Colonies from the Patients with Cancer Receiving Chemotherapy in China

Clinical Distribution and Drug Sensitivity of 486 Strains of Candida in 1,690 Specimens

Species Identification and Antifungal Susceptibility Testing of Isolates from Patients with Vulvovaginal Candidiasis

Observing the Susceptibility of Candida Albicans Challenge with Fluconazole and Itraconazole by M27-A Microdilution Method

Antifungal Susceptibility Testing of Candida Albicans Isolated from Recurrent Vulvovaginal Candidiasis

Drug resistance and genotypes of oral Candida albicans and expressions of drug-resistant genes of oral Candida albicans

Influence of Prophylactic Application of Fluconazole on Antifungal Susceptibility to Strains of Candida Isolated from the Patients with High Risk of Deep Fungal Infections

Species identification and antifungal susceptibility of 128 strains of yeast fungi

The sensitivity testing in vitro of major Candida to terconazole

[Antifungal Susceptibility Test of Genotypes of Candida Albicans from Patients with Atrophic or Erosive Oral Lichen Planus].

Drug-resistance of oral cultured candida spp.In HIV positive patients